Pharmacogenetics of Metabolic Bone Diseases
Francesca Marini and Maria Luisa Brandi*
Metabolic Bone Unit, Department of Internal Medicine, University of Florence, Florence, Italy
- *Corresponding Author:
- Maria Luisa Brandi, M.D., Ph.D.
Metabolic Bone Unit, Department of Internal Medicine
University of Florence, Largo Palagi 1, 50139 Florence, Italy.
Tel: +39 055 7946304
Fax: +39 055 7946303
E-mail: [email protected]
Received date: April 05, 2012; Accepted date:May 11, 2012; Published date: May 14, 2012
Citation: Marini F, Brandi ML (2012) Pharmacogenetics of Metabolic Bone Diseases. J Pharmacogenomics Pharmacoproteomics 3:109. doi: 10.4172/2153-0645.1000109
Copyright: © 2012 Marini F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Individual drug response results to be highly variable among treated patients for many of the most commonly prescribed drugs. Common sequence variants in the human genome are today believed to be the main cause of different individual drug response.
Pharmacogenetics applies the principles of both pharmacology and genetics, for the discovery and validation of functional gene polymorphisms that could be relevant in the modulation of the pharmacodynamics and pharmacokinetics of drugs, in order to be able to predict the personal response to drugs both in terms of beneficial and adverse effects.
A more and more growing number of pharmacogenetic studies have been performed in the last decade, but, to date, only few of them have validated clinical application. This is even more true in the field of bone disorders in which pharmacogenetic studies are still very limited.
This review will offer an overview on current pharmacogenetic applications, especially focusing on
pharmacogenetic studies in the field of osteoporosis and metabolic bone diseases.